La Jolla Pharma (LJPC) 16.48 $LJPC La Jolla

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
La Jolla Pharma (LJPC) 16.48 $LJPC

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2016
BusinessWire - Mon Aug 08, 3:44PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and six months ended June 30, 2016.
LJPC: 16.48 (+0.13)

The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
The Zacks Analyst Blog Highlights: Aratana Therapeutics, Dynavax Technologies, Heron Therapeutics and La Jolla Pharmaceutical
DVAX: 15.94 (+0.28), HRTX: 18.33 (-0.27), LJPC: 16.48 (+0.13), PETX: 8.92 (+0.05)

Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:33AM CDT
What's in store for drug stocks Dynavax, Aratana and others when they report their Q2 results on Aug 5?
DVAX: 15.94 (+0.28), JNJ: 119.08 (-0.26), HRTX: 18.33 (-0.27), GILD: 77.42 (-0.96), LJPC: 16.48 (+0.13), PETX: 8.92 (+0.05)

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference
BusinessWire - Mon Jun 06, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will provide a corporate overview at the Jefferies 2016 Global Healthcare Conference taking place June 7-10 in New York City.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical posts 1Q loss
Automated Insights - Fri May 06, 8:07AM CDT
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Friday reported a loss of $16.5 million in its first quarter.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress
BusinessWire - Fri May 06, 8:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2016 financial results and highlighted recent corporate progress.
LJPC: 16.48 (+0.13)

New 52-Week Low Could Prompt More Insider Buying At LJPC
TheOnlineInvestor.com - Fri Jan 15, 12:28PM CST
In trading on Friday, shares of La Jolla Pharmaceutical Co. touched a new 52-week low of $14.01/share.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
BusinessWire - Mon Nov 30, 7:00AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/575,127, entitled "Angiotensin II Alone or in Combination for the Treatment of Hypotension," which covers LJPC-501, La Jolla's proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). LJPC-501 is currently the subject of a Phase 3 clinical trial for the treatment of CRH, and results from this trial are expected by the end of 2016.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload
BusinessWire - Mon Oct 19, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been dosed in a Phase 1 clinical trial of LJPC-401, La Jolla's novel formulation of hepcidin.
LJPC: 16.48 (+0.13)

Orphan Drug Designation For Novel Compounds - Report on La Jolla Pharmaceutical
PR Newswire - Wed Sep 16, 8:20AM CDT
ACI Association has initiated research coverage on La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company concludes public offering of 2.93m common stock
M2 - Wed Sep 16, 4:35AM CDT
Biopharmaceutical company La Jolla Pharmaceutical Company (Nasdaq:LJPC) reported on Tuesday that it has completed its underwritten public offering of 2,932,500 shares of common stock.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company Closes Offering of Common Stock
BusinessWire - Tue Sep 15, 3:10PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla", a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the closing of its underwritten public offering of 2,932,500 shares of common stock at a public offering price of $38.00 per share, which includes the exercise of the underwriters' option to purchase up to an additional 382,500 shares of common stock. Gross offering proceeds are approximately $111.4 million, including proceeds from the exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
BusinessWire - Fri Sep 11, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla", a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending LJPC-401, La Jolla's novel formulation of hepcidin, for designation as an orphan medicinal product for the treatment of chronic iron overload requiring chelation therapy. Chronic iron overload occurs in patients suffering from beta thalassemia, sickle cell disease and hereditary hemochromatosis (HH). The final opinion, which is subject to review and approval by the European Commission (EC), may include all or a subset of these conditions.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
BusinessWire - Thu Sep 10, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla", a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten offering of 2,550,000 shares of its common stock, offered at a price of $38.00 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 382,500 shares of common stock. The offering is expected to close on or about September 15, 2015, subject to customary closing conditions. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Chardan Capital Markets, LLC, LifeSci Capital LLC and Noble Life Science Partners are acting as co-managers for the offering.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical Company to launch underwritten offering of common shares
M2 - Thu Sep 10, 3:26AM CDT
Biopharmaceutical therapies company La Jolla Pharmaceutical Company (Nasdaq:LJPC) stated on Wednesday that it plans to offer its common stock in an underwritten offering.
LJPC: 16.48 (+0.13)

La Jolla Pharmaceutical (LJPC) in Focus: Stock Rises 26.5%
Zacks Equity Research - Zacks Investment Research - Wed Sep 09, 8:48AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as its shares rose almost 27% on the day.
LJPC: 16.48 (+0.13), IG: 7.68 (+1.41)

La Jolla Pharmaceutical (LJPC) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 7:59AM CDT
La Jolla Pharmaceutical (LJPC) is Overbought: Is A Drop Coming?
LJPC: 16.48 (+0.13)

3 Biotech Stocks Bucking the Stock Market Crash
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 28, 1:02PM CDT
Source: National Cancer Institute. The past week on Wall Street has been downright ugly. For five straight sessions panic has pushed all three major market indexes lower by double-digit percentages. Although stock market corrections are a...
LXRX: 14.33 (+0.45), LJPC: 16.48 (+0.13), ACOR: 24.34 (+0.26)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading